GlassScriptPhysician profile
David J Widmyer
NPI 1396972246
$2,602.14
in general payments reported to CMS, 2019-2025
21 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $217 · 2021: $461 · 2022: $419 · 2023: $598 · 2024: $350 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.00 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $288.94 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $262.55 | 2019-2023 | Auryxia |
| Astrazeneca Pharmaceuticals LP | $222.66 | 2019-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $204.98 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $202.69 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $195.27 | 2019-2024 | Rayaldee |
| Cvrx, INC. | $178.39 | 2024 | Barostim Neo System |
| Vifor Pharma, INC. | $152.04 | 2019-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $134.99 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $121.82 | 2021-2024 | Ultomiris |
| Bard Peripheral Vascular, INC. | $108.46 | 2020 | |
| Aurinia Pharma U.S., INC. | $84.33 | 2021-2023 | Lupkynis |
| Amgen INC. | $83.87 | 2022-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $79.62 | 2023-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $63.09 | 2023-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $61.55 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $48.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.34 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $34.32 | 2023-2025 | |
| Lilly USA, LLC | $22.20 | 2024 | Jardiance |
| Abbvie INC. | $17.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Widmyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.